Intuniv (Guanfacine ER)
NONSTIMULANTS · ALPHA-2A ADRENERGIC AGONIST · EXTENDED-RELEASE TABLETS
Key facts
- Drug class
- Alpha-2A Adrenergic Agonist · Nonstimulants
- Active ingredient
- guanfacine
- Studied ages (label)
- 6–17 years (monotherapy or adjunct to a stimulant)
- Form and strengths
- Extended-release tablet; 1 mg, 2 mg, 3 mg, 4 mg extended-release tablets
- Usual dose and maximum (label)
- Start 1 mg once daily, increasing by no more than 1 mg per week; target 0.05–0.12 mg/kg/day (1–7 mg/day).
- Duration
- Taken once daily, every day; the label does not describe hour-by-hour effects (half-life about 18 hours).
- DEA schedule
- Not a controlled substance
- Generic
- AB-rated generics (see Generic manufacturers)
- Label date
- Prescribing Information revised 06/2025 (DailyMed)
Label last checked: Oct 2026 — Prescribing Information revised 06/2025 (DailyMed) · Last medical review: November 12, 2026
Educational information only, not medical advice. Do not start, stop or change a medication without your prescriber. Medical disclaimer
What it is
Intuniv is a nonstimulant tablet taken once a day, morning or evening, every day. It is not a controlled substance. It can be used by itself or together with a stimulant. Generic guanfacine ER tablets are available.
Do not stop suddenly: abrupt discontinuation of an alpha-2 agonist can cause rebound hypertension (labels describe headache, tachycardia, nausea, flushing and rapid rises in blood pressure; hypertensive encephalopathy has been reported with guanfacine). Taper as directed, and watch for missed doses during vomiting illnesses.
Central alpha-2A-adrenergic receptor agonist (guanfacine initial U.S. approval 1986) indicated for ADHD as monotherapy and as adjunctive therapy to stimulant medications. Efficacy was studied in ages 6–17 (safety and efficacy under 6 not established). No boxed warning. NDA 022037 (Takeda), 1/2/3/4 mg; AB-rated generics. Not interchangeable mg-for-mg with immediate-release guanfacine (relative bioavailability 58%; Cmax 60% lower).
When considering this for a patient
Guanfacine ER is often considered when hyperactivity or impulsivity is prominent, when stimulants are not tolerated or are only partly effective (it is labeled as add-on therapy to stimulants), or when a non-controlled medicine is preferred. These are clinical-practice reasons; the label’s own studies were in ages 6–17.
Measure heart rate and blood pressure before starting, after dose increases, and periodically. Titrate slowly in patients at risk for hypotension, bradycardia, heart block or syncope; avoid dehydration and overheating. Sedation is common; consider additive effects with CNS depressants. Plan a taper when stopping.
Patient profile and niche
Guanfacine ER may be particularly useful in the following situations:
- Children and teens 6–17 who need a nonstimulant, or extra symptom control on top of a stimulant.
- Families who prefer a non-controlled, once-daily medicine.
- Patients who could not tolerate stimulants because of appetite or sleep effects.
- Situations where an evening dose fits the routine (the label allows morning or evening dosing).
Less suited when low blood pressure, slow heart rate or fainting are concerns, when daytime sleepiness would be a problem, or when missed doses are likely (rebound hypertension). Use in adults is not established by the label. These are clinical considerations, not label-studied subgroups.
When it is active
Intuniv is taken once a day, every day. With a half-life of roughly 18 hours, blood levels stay present around the clock once steady state is reached, rising about 5 hours after each dose (6 hours in adult PK studies). The label does not describe hour-by-hour effects; doses are increased weekly and trials measured benefit over several weeks.
The chart shows the schematic steady-state blood level across 24 hours for your dose time. Sleepiness is often most noticeable when starting or raising the dose.
Enter your usual dose time and day. The curve shows the schematic blood level after several days of daily dosing (steady state), across a full 24 hours. It does not show when the medicine ‘works’: for this medicine, benefit is judged over weeks, not hour by hour.
The curve shows relative blood level, not clinical effect. Benefit is judged over weeks of daily dosing and titration.
Everyone is different. This is a schematic based on labeling data, not a prediction for any one person.
How it works
Guanfacine stimulates alpha-2A receptors in the brain. It is not a stimulant and does not block dopamine or norepinephrine transporters. The same action lowers blood pressure and heart rate, which is why those are monitored.
15–20× higher affinity for α2A than α2B/α2C
Per labeling, guanfacine is a central alpha-2A-adrenergic receptor agonist and is not a CNS stimulant; its mechanism of action in ADHD is not known. It is a known antihypertensive: stimulating central alpha-2A receptors reduces sympathetic outflow, lowering vascular resistance, blood pressure and heart rate. Guanfacine is primarily metabolized by CYP3A4 (label 12.3).
Formulations and duration
Once-daily extended-release tablets. Swallow whole; do not crush, chew or break (this increases the rate of release). Do not take with a high-fat meal.
| STRENGTHS | 1 mg, 2 mg, 3 mg, 4 mg extended-release tablets |
|---|---|
| STUDIED AGES | 6–17 years (monotherapy or adjunct to a stimulant) |
| DOSING | Once daily, morning or evening, at about the same time each day |
| CONTROLLED STATUS | Not a controlled substance |
| SWITCHING | Not mg-for-mg with immediate-release guanfacine; stop IR and titrate Intuniv |
Missed doses: after two or more consecutive missed doses, consider re-titration based on tolerability.
Appearance
Intuniv tablets (FDA label; bottles of 100):
- 1 mg — white/off-white, round, “503” / “1 mg” (NDC 54092-513-02)
- 2 mg — white/off-white, caplet, “503” / “2 mg” (NDC 54092-515-02)
- 3 mg — green, round, “503” / “3 mg” (NDC 54092-517-02)
- 4 mg — green, caplet, “503” / “4 mg” (NDC 54092-519-02)
Generic guanfacine ER tablets look different by manufacturer. Check the bottle label for the strength.
Official package photos and pill identifiers:
Generic manufacturers
Many companies make AB-rated guanfacine extended-release tablets in all four strengths.
| Product | Notes |
|---|---|
| Intuniv (Takeda) | NDA 022037; reference listed drug (4 mg is the reference standard) |
| AB-rated guanfacine ER (Orange Book, RX) | Alembic, Apotex, Fosun Wanbang, Rubicon, Sandoz, Teva, TWI, Unichem, Yichang Humanwell; Actavis also listed RX |
| Actavis (Teva) guanfacine ER | FDA Drug Shortages lists a business-decision discontinuation of all four strengths (posted Nov 13, 2025) |
Orange Book (October 2026): guanfacine ER ANDAs from Impax, Pharmobedient and Sun are DISCN. The FDA discontinuation notice for Actavis is not a shortage.
Common side effects
Do not stop suddenly: abrupt discontinuation of an alpha-2 agonist can cause rebound hypertension (labels describe headache, tachycardia, nausea, flushing and rapid rises in blood pressure; hypertensive encephalopathy has been reported with guanfacine). Taper as directed, and watch for missed doses during vomiting illnesses.
Common side effects include sleepiness, tiredness, low blood pressure, stomach pain, headache, dizziness, dry mouth, irritability and nausea. Sleepiness is often most noticeable when starting or raising the dose.
In a special heart-rhythm study in healthy adults, usual and high doses of guanfacine did not prolong the QT interval when the reading was corrected for heart rate in the planned way. A secondary method had one reading just over the usual cutoff after the high dose. The study used immediate-release guanfacine, not the extended-release tablet itself.
| EFFECT | FREQUENCY | NOTES |
|---|---|---|
| Sleepiness / sedation | Common | Caution with driving; often lessens over time |
| Tiredness / lethargy | Common | |
| Low blood pressure, slow heart rate, fainting | Common to uncommon | Monitored; avoid dehydration and overheating |
| Stomach pain / nausea | Common | |
| Dizziness, dry mouth, irritability | Common | |
| Rebound high blood pressure if stopped suddenly | Serious | Always taper |
Most common adverse reactions (≥5% and ≥2× placebo): fixed-dose monotherapy — hypotension, somnolence, fatigue, nausea, lethargy; flexible-dose — somnolence, hypotension, abdominal pain, insomnia, fatigue, dizziness, dry mouth, irritability, nausea, vomiting, bradycardia; adjunctive — somnolence, fatigue, insomnia, dizziness, abdominal pain. Warnings: hypotension, bradycardia, syncope; sedation and somnolence; cardiac conduction abnormalities (may worsen sinus node dysfunction and AV block, especially with other sympatholytics); rebound hypertension with hypertensive encephalopathy reported after abrupt discontinuation. Contraindication: hypersensitivity to guanfacine products.
Outside the label (thorough QT study; see Clinical evidence from published studies, Heart and blood pressure): in 83 healthy adults, immediate-release guanfacine 4 mg and 8 mg did not prolong QT after individualized correction (QTcNi largest 1-sided 95% UCB through 12 h was 1.94 ms). With Fridericia correction, one 1-sided 95% UCB was 10.34 ms at 12 h after the 8 mg dose, the only bound >10 ms (Martin 2015, PubMed 25109412). This was a study of immediate-release guanfacine, not Intuniv tablets.
Dosing considerations
Start at 1 mg once a day and increase by no more than 1 mg per week. Most children and teens end up between 0.05 and 0.12 mg per kg per day.
Target 0.05–0.12 mg/kg/day (1–7 mg/day). Doses above 4 mg/day were not evaluated in ages 6–12, and above 7 mg/day not in ages 13–17. CYP3A4: with strong or moderate CYP3A4 inhibitors (e.g. ketoconazole), use half the recommended dose; with strong or moderate inducers (e.g. carbamazepine), consider up to double over 1–2 weeks, and reverse these changes when the interacting drug is stopped. Renal or hepatic impairment: dose reduction may be necessary. Discontinuation: taper by no more than 1 mg every 3–7 days and monitor blood pressure and pulse.
| Weight | Target dose range (0.05–0.12 mg/kg/day) |
|---|---|
| 25–33.9 kg | 2–3 mg/day |
| 34–41.4 kg | 2–4 mg/day |
| 41.5–49.4 kg | 3–5 mg/day |
| 49.5–58.4 kg | 3–6 mg/day |
| 58.5–91 kg | 4–7 mg/day |
| Over 91 kg | 5–7 mg/day |
When Intuniv is added to a stimulant, the label notes most patients reached optimal doses in the same 0.05–0.12 mg/kg/day range.
Pregnancy and breastfeeding
Tell your clinician if you are pregnant, plan to become pregnant, or are breastfeeding. Decades of guanfacine use have not shown a higher risk of major birth defects or miscarriage, although it has not often been used in pregnancy.
It is not known whether guanfacine passes into human breast milk; it does pass into animal milk. If a breastfed baby is exposed, watch for sleepiness, unusual tiredness, or poor feeding, which can be signs of low blood pressure or a slow heart rate. Decide about breastfeeding together with your clinician.
A national pregnancy registry collects information about ADHD medicines used during pregnancy. You or your clinician can enroll by calling 1-866-961-2388.
Pregnancy (label 8.1): available data over decades of guanfacine use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, although use in pregnancy has been infrequent. Animal data: guanfacine crosses the placenta in rats; no fetal harm in rabbits and rats at 3 and 4 times the MRHD, but reduced fetal survival and maternal toxicity at 13.5 times the MRHD. Registry: National Pregnancy Registry for ADHD Medications (as named in the label), 1-866-961-2388.
Lactation (label 8.2): no data on guanfacine in human milk, effects on the breastfed infant, or milk production; guanfacine is present in rat milk and is likely to be present in human milk. Monitor exposed infants for signs of hypotension and bradycardia (sedation, lethargy, poor feeding). Weigh the benefits of breastfeeding against the mother’s clinical need for Intuniv and any potential effects on the child.
Outside the label: LactMed (NCBI Bookshelf, “Guanfacine,” revised Nov 2024; NBK501522) says no information is available on use during breastfeeding and, because of possible negative effects on lactation, other agents may be preferred, especially while nursing a newborn or preterm infant. This is LactMed’s summary of published data, not FDA label content.
Availability and shortages
MARKETED Intuniv and multiple generic guanfacine ER tablets are available. Guanfacine ER is not on the FDA current-shortage list or the ASHP shortage list as of October 20, 2026.
One generic maker (Actavis) has a business-decision discontinuation posted on the FDA site; other generics remain listed.
Checked Oct 20, 2026: ASHP current list — no guanfacine entry. FDA Drug Shortages — guanfacine ER tablets appear only under ‘Discontinuation’ (Actavis Pharma, 1–4 mg, posted Nov 13, 2025). Orange Book: Intuniv RX.
How Intuniv compares to other nonstimulant options
Rows summarize each product’s FDA labeling; they are not head-to-head comparisons. Unlike stimulants, atomoxetine, viloxazine, guanfacine and clonidine are not controlled substances and are taken every day for continuous coverage, with benefit judged over weeks of titration rather than hours after a dose.
| Medication | Class / action (label) | Dosing and time course | Controlled status / boxed warning | Key safety and practical notes |
|---|---|---|---|---|
| Intuniv (guanfacine ER tablet) | Central α2A-adrenergic agonist | Once daily (AM or PM); +1 mg/week max; trials up to 15 weeks | Not controlled · No boxed warning | Rebound hypertension if stopped abruptly (taper ≤1 mg every 3–7 days). CYP3A4 dose adjustments. Ages 6–17 studied. AB generics. |
| Clonidine ER tablets (Kapvay discontinued) | Centrally acting α2-adrenergic agonist | Twice daily (equal or larger bedtime dose); +0.1 mg/week; max 0.4 mg/day | Not controlled · No boxed warning | Rebound hypertension if stopped abruptly (taper ≤0.1 mg every 3–7 days). Ages 6–17. Kapvay brand discontinued; AB1 generics. |
| Onyda XR (clonidine ER oral suspension) | Centrally acting α2-adrenergic agonist | Once daily at bedtime; +0.1 mg/week; max 0.4 mg | Not controlled · No boxed warning | Rebound hypertension if stopped abruptly (taper ≤0.1 mg every 3–7 days). Liquid 0.1 mg/mL; not mg-for-mg with other clonidine. Ages 6+. |
| Atomoxetine (Strattera; generics; Atoncy solution) | Selective norepinephrine reuptake inhibitor | Once daily or split twice daily; titrate after ≥3 days; acute trials up to 18 weeks | Not controlled · Boxed warning: suicidal thoughts (ages 6+) | CYP2D6 poor metabolizers/strong 2D6 inhibitors: 4-week titration interval; label states start, target and maximum unchanged. Liver injury warning. Brand discontinued; AB generics. |
| Qelbree (viloxazine ER capsule) | Selective norepinephrine reuptake inhibitor (also 5-HT2C partial agonist) | Once daily; weekly titration; steady state in 2 days; trials 6–8 weeks | Not controlled · Boxed warning: suicidal thoughts (all ages) | Strong CYP1A2 inhibitor: contraindicated with sensitive/narrow-range CYP1A2 substrates. Sprinkle allowed. Brand only. |
| Simtriyo (centanafadine ER capsule) | Norepinephrine-dopamine-serotonin reuptake inhibitor; labeled a CNS stimulant | Once daily in the morning; fixed weight-/age-based doses; trials 6 weeks | Schedule III (CIII) · Boxed warnings: pediatric suicidality; abuse/misuse | Approved Jul 24, 2026; DEA Schedule III since Oct 30, 2026; now marketable (check pharmacy availability). Moderate CYP1A2 inhibitor. Ages 6+ and ≥20 kg. |
| Stimulants for contrast (e.g. Concerta, Vyvanse) | Methylphenidate or amphetamine: block (and for amphetamines, release) dopamine and norepinephrine | Effects begin within hours of each dose and wear off the same day (timing depends on formulation; see each label) | Schedule II · Boxed warning: abuse, misuse and addiction | Coverage is tied to dosing time each day, unlike the continuous steady-state coverage of atomoxetine, viloxazine and the alpha-2 agonists. |
Other nonstimulant and newer-mechanism pages: Strattera (atomoxetine), Atoncy (atomoxetine solution), Qelbree, Kapvay (clonidine ER), Onyda XR, Simtriyo. Stimulant overviews: methylphenidate (Ritalin) and amphetamine (Adderall) family pages.
Clinical evidence from published studies
These findings come from published research, not from the FDA label. The FDA label is the official source for approved uses, doses and warnings. Results from studies may not apply to you. Uses marked off-label are not FDA-approved. Talk with your prescriber before making any change.
Items summarize peer-reviewed publications, checked against the PubMed abstract (or full text where stated); figures are reproduced only where the source states them. The FDA label governs approved indications and dosing. Off-label items are not FDA-approved uses. Industry funding or sponsor affiliation is noted where the PubMed record shows it; absence of a note does not mean no industry involvement.
Studies of this medicine (8 studies)
-
Intuniv (guanfacine ER), children 6–17
In a trial of 345 children and teens, guanfacine ER 2, 3 or 4 mg reduced ADHD symptom scores by about 16–19 points vs 8.5 on placebo, with improvements on teacher and parent ratings.
RCT, 345 randomized (placebo 86; 2 mg 87; 3 mg 86; 4 mg 86): ADHD-RS-IV −16.18 / −16.43 / −18.87 vs −8.48.
Biederman J, Melmed RD, Patel A, et al. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121(1):e73-84. DOI · PubMed 18166547
-
Intuniv (guanfacine ER), atomoxetine reference arm
In a trial of children and teens aged 6–17 in Europe and North America, guanfacine ER reduced ADHD symptoms by about 9 points more than placebo. Atomoxetine, included only as a reference, reduced them by about 4 points more than placebo. The trial was not designed to compare the two directly.
RCT with ATX reference arm (dose-optimised; 4 or 7 weeks); 272 (80.5%) completed. Placebo-adjusted ADHD-RS-IV: GXR −8.9 (p<0.001); ATX −3.8 (p<0.05). CGI-I improved difference vs placebo: GXR 23.7, ATX 12.1 percentage points.
Funding / affiliation: Shire-affiliated authors per PubMed record.
Hervas A, Huss M, Johnson M, et al. (2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol 24(12):1861-72. DOI · PubMed 25453486
-
Intuniv (guanfacine ER), adolescents 13–17
In 314 adolescents aged 13–17, guanfacine ER reduced ADHD symptoms more than placebo (a moderate effect). Nearly half were optimized to doses above the 4 mg maximum that was approved at the time.
RCT, 314 randomized (157/157): ADHD-RS-IV −24.55 vs −18.53 (ES 0.52; p<.001); 46.5% optimal dose >4 mg; WFIRS-P domains NS at week 13.
Funding / affiliation: Shire-affiliated authors per PubMed record.
Wilens TE, Robertson B, Sikirica V, et al. (2015). A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 54(11):916-25.e2. DOI · PubMed 26506582
-
Intuniv (guanfacine ER): morning vs evening dosing
In 333 children, guanfacine ER worked about equally well whether taken in the morning or evening. Sleepiness was common with either timing (42–47%, vs 13% on placebo).
RCT: GXR AM n=107, PM n=114, placebo n=112. ADHD-RS-IV −19.8 (AM) / −20.1 (PM) vs −11.0 (p<.001). Somnolence 46.7% / 42.1% / 12.5%.
Newcorn JH, Stein MA, Childress AC, et al. (2013). Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry 52(9):921-30. DOI · PubMed 23972694
-
Intuniv (guanfacine ER) added to a stimulant
In children and teens with only a partial response to a stimulant, adding morning or evening guanfacine ER reduced ADHD symptoms more than adding placebo. No new safety signals were seen.
Adjunctive RCT (N=461 per abstract): ADHD-RS-IV GXR AM p=.002, PM p<.001 vs placebo + stimulant; small decreases in pulse and BP.
Wilens TE, Bukstein O, Brams M, et al. (2012). A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 51(1):74-85.e2. DOI · PubMed 22176941
-
Intuniv (guanfacine ER) added to a stimulant
In a further analysis of the add-on trial, about 63–65% of those adding guanfacine ER had at least a 50% symptom reduction vs 43% adding placebo.
Post hoc: ≥50% ADHD-RS-IV reduction 63.1% (AM) / 64.9% (PM) vs 43.4% placebo.
Funding / affiliation: Industry: Shire authors per PubMed record.
Cutler AJ, Brams M, Bukstein O, et al. (2014). Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 53(10):1092-101. DOI · PubMed 25245353
-
Guanfacine XR: randomized withdrawal (maintenance of effect)
In children and teens who were already doing well on guanfacine, those who stayed on it were less likely to lose their response over the next 26 weeks than those switched to a placebo (about 49 in 100 vs about 65 in 100).
Open-label GXR (1–7 mg/day) in children/adolescents aged 6–17; after 13 weeks, responders were randomised to GXR or placebo in a 26-week double-blind randomised-withdrawal phase. 528 participants enrolled; 316 (59.8%) entered the RWP. Treatment failure occurred in 49.3% of the GXR group and 64.9% of the placebo group (p=0.006). Time to treatment failure was significantly longer with GXR (p=0.003).
Funding / affiliation: Authors affiliated with Shire (then the manufacturer of Intuniv).
Newcorn JH, Harpin V, Huss M, et al. (2016). Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry 57(6):717-28. DOI · PubMed 26871297
-
Guanfacine XR: timing of efficacy vs sedation
In a closer look at guanfacine trials, ADHD symptom improvement built up from weeks 1 to 4 and then stayed about the same, while sleepiness as a side effect generally appeared early. This is a secondary analysis, not a new trial.
Post-hoc analysis distinguishing efficacy and sedative effects of guanfacine extended release. Efficacy (ADHD-RS or similar core measure, as reported) increased from weeks 1 to 4 and remained stable to study endpoint. Sedative treatment-emergent adverse events generally emerged early. Qualitative timing only; no new effect-size is taken from this abstract.
Huss M, McBurnett K, Cutler AJ, et al. (2019). Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 29(3):432-443. DOI · PubMed 30064718
How ADHD medicines compare (8 studies)
-
Guanfacine ER vs atomoxetine (indirect)
With no head-to-head trial available, this industry-funded study statistically matched patients across separate trials and estimated that guanfacine ER reduced symptoms more than atomoxetine. Matched indirect comparisons are weaker evidence than a direct trial.
Matching-adjusted indirect comparison (guanfacine ER individual patient data vs published atomoxetine aggregate data). Base case: additional ADHD-RS-IV reduction with GXR vs ATX −7.0 (SE 2.2; p<0.01); hyperactivity/impulsivity −3.8, inattention −3.2. Consistent in sensitivity analyses.
Funding / affiliation: Industry: lead author affiliated with Shire (guanfacine ER manufacturer) per PubMed record.
Sikirica V, Findling RL, Signorovitch J, et al. (2013). Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs 27(11):943-53. DOI · PubMed 23975660
-
ADHD medicines in children (class)
An industry-funded network analysis of 36 trials ranked placebo-adjusted symptom improvement as largest for lisdexamfetamine, then extended-release methylphenidate, then guanfacine ER, then atomoxetine. These are indirect comparisons.
Bayesian NMA of 36 RCTs (6–17 y). ADHD-RS-IV change vs placebo: lisdexamfetamine −14.98 (95% CrI −17.14 to −12.80), MPH ER −9.33 (−11.63 to −7.04), guanfacine ER −8.68 (−10.63 to −6.72), atomoxetine −6.88 (−8.22 to −5.49).
Funding / affiliation: Authors affiliated with Shire (guanfacine ER and lisdexamfetamine manufacturer) per PubMed record.
Joseph A, Ayyagari R, Xie M, et al. (2017). Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry 26(8):875-897. DOI · PubMed 28258319
-
ADHD medicines (class)
A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.
Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.
Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).
Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390
-
ADHD treatments in children and teens (class)
Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems.
Bayesian network meta-analyses of 190 RCTs (52 interventions, 26,114 participants; ≥3 weeks follow-up). Medications more efficacious than placebo: methylphenidate, amphetamine, atomoxetine, guanfacine, clonidine. Methylphenidate and amphetamine more efficacious than atomoxetine and guanfacine; methylphenidate and clonidine better accepted (all-cause discontinuation) than placebo and atomoxetine. Behavioural therapy plus stimulants appeared superior to stimulants or nonstimulants alone. Harms included anorexia, weight loss and insomnia. Results expressed as ORs with credible intervals (not reproduced here).
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 12(7):e0180355. DOI · PubMed 28700715
-
ADHD medicines (class): dose
An analysis of how benefit changes with dose (113 trials) found that, in children and teens, extra benefit stopped rising above about 45 mg/day of methylphenidate, 25 mg/day of amphetamines and 4 mg/day of guanfacine, although data at higher doses were thin. Stopping for side effects rose at higher amphetamine doses, and at methylphenidate doses above 50 mg/day in adults. No dose–benefit pattern was found for atomoxetine in fixed-dose studies.
Dose-effect NMA (Bayesian restricted cubic splines) of 113 double-blind RCTs: 68 pediatric (14,138 participants), 45 adult (11,016). Children/adolescents: median efficacy increased up to ~45 mg/day methylphenidate, ~25 mg/day amphetamines, ~4 mg/day guanfacine, with no evidence of added benefit above (wide credible intervals). Adults: amphetamines plateaued above ~50 mg/day; methylphenidate showed no plateau (sparse data). Dose-dependent AE-related discontinuation: amphetamines above 25 mg/day (children) and 50 mg/day (adults); methylphenidate above 50 mg/day in adults, no clear dose dependence in children. No dose-effect pattern for atomoxetine (fixed-dose studies) or modafinil. Needs full-text check: how amphetamine products were converted to a common dose scale is not stated in the abstract.
Funding / affiliation: Non-industry (UK NIHR).
Nourredine M, Jurek L, Hamza T, et al. (2026). Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Lancet Psychiatry 13(6):485-495. DOI · PubMed 42134365
-
Adult ADHD treatments (class)
In adults (113 trials), stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-ratings and clinician ratings at 12 weeks. Several psychological approaches (such as CBT and mindfulness) helped only on clinician ratings. Atomoxetine and guanfacine were stopped more often than placebo.
Component NMA, 113 RCTs (14,887 adults). 12-week core symptoms: atomoxetine SMD −0.38 self-rated (−0.56 to −0.21), −0.51 clinician-rated (−0.64 to −0.37); stimulants about −0.39 self-rated (CI −0.52 to −0.26) and −0.61 clinician-rated (−0.71 to −0.51). CBT (−0.76), cognitive remediation, mindfulness, psychoeducation and tDCS beat placebo on clinician-rated measures only. Acceptability worse than placebo: atomoxetine OR 1.43 (1.14–1.80), guanfacine 3.70 (1.22–11.19).
Ostinelli EG, Schulze M, Zangani C, et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry 12(1):32-43. DOI · PubMed 39701638
-
Guanfacine vs placebo: CGI-I response (pooled trials)
A review of guanfacine trials found that people on guanfacine were more likely than those on placebo to be rated much or very much improved — about 1.8 times the response rate. The review pooled guanfacine studies and did not report Intuniv separately.
This review pooled guanfacine trials; it did not report Intuniv separately.
Meta-analysis of 12 RCTs (2,653 participants) vs placebo, primary outcome CGI-I ≤2: RR 1.78 (95% CI 1.59–2.01). This item reports only the overall CGI-I risk ratio from the abstract. It does not use 59.8% vs 34.0% or 9.3% vs 1.9% figures, which are not in this abstract. The review pooled guanfacine trials; it did not report Intuniv (guanfacine XR) separately.
Yu S, Shen S, Tao M (2023). Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis. J Child Adolesc Psychopharmacol 33(2):40-50. DOI · PubMed 36944092
-
Atomoxetine, guanfacine and viloxazine ER in adults vs placebo
A review of adult trials found that atomoxetine and guanfacine reduced ADHD symptoms more than placebo. Guanfacine is not FDA-approved for ADHD in adults in the United States. The review also included one viloxazine ER trial. These are average results across studies, not a comparison of one brand with another.
This review pooled adult trials of atomoxetine, guanfacine and viloxazine ER; it did not report this product separately. Guanfacine is not FDA-approved for ADHD in adults in the United States.
Random-effects meta-analysis updating Cortese 2018; 18 studies (4,308 participants) plus one additional study in a narrative synthesis (374 participants). Atomoxetine (15 RCTs) Hedges’ g = −0.48 (95% CI −0.64 to −0.33); guanfacine (two RCTs) g = −0.66 (−0.94 to −0.38); viloxazine ER (one RCT) was also significantly more efficacious than placebo. Guanfacine is not FDA-approved for ADHD in adults in the US. The abstract does not report 9.3% vs 3.6% adverse-event figures.
Radonjić NV, Bellato A, Khoury NM, et al. (2023). Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. CNS Drugs 37(5):381-397. DOI · PubMed 37166701
Heart and blood pressure (2 studies)
-
ADHD medicines (class)
Pooling 102 short-term trials, most ADHD medicines raised blood pressure and pulse modestly, and stimulants did not raise them more than atomoxetine or viloxazine. Guanfacine lowered blood pressure and pulse. The authors advise monitoring blood pressure and pulse with any ADHD medicine, not just stimulants.
NMA of 102 RCTs (13,315 children/adolescents; 9,387 adults; median 7 weeks). Children, mean increase vs placebo: SBP 1.07 (atomoxetine) to 1.81 mm Hg (methylphenidate); DBP 1.93 (amphetamines) to 2.42 (methylphenidate); pulse 2.79 bpm (viloxazine) to 5.58 bpm (atomoxetine). Amphetamines, lisdexamfetamine and methylphenidate not associated with larger increments than atomoxetine or viloxazine. Guanfacine in children: SBP −2.83 (−3.8 to −1.85), DBP −2.08, pulse −4.06. Only four RCTs informed medium-term effects. CINeMA confidence mostly low to moderate in children, very low in adults.
Funding / affiliation: Non-industry (UK NIHR).
Farhat LC, Lannes A, Del Giovane C, et al. (2025). Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 12(5):355-365. DOI · PubMed 40203844
-
Thorough QT study of guanfacine (immediate-release, 4 and 8 mg)
In a special heart-rhythm study in healthy adults, usual and high doses of guanfacine did not prolong the QT interval when the reading was corrected for heart rate in the planned way. A secondary correction method had one reading just over the usual cutoff after the high dose. This study used immediate-release guanfacine, not the extended-release tablet itself.
Thorough QT, double-blind, 3-period crossover in 83 healthy adults: immediate-release guanfacine 4 mg (therapeutic) and 8 mg (supra-therapeutic), placebo, and moxifloxacin 400 mg. QTcNi: largest 1-sided 95% upper confidence bound through hour 12 was 1.94 ms. QTcF: largest 1-sided 95% UCB was 10.34 ms at 12 hours after the supra-therapeutic dose, the only 1-sided 95% UCB >10 ms. Conclusions: neither therapeutic nor supra-therapeutic doses prolonged QT interval after individualized correction (QTcNi) through 12 hours postdose.
Martin P, Satin L, Kahn RS, et al. (2015). A thorough QT study of guanfacine. Int J Clin Pharmacol Ther 53(4):301-16. DOI · PubMed 25109412
ADHD with other conditions (2 studies)
-
Intuniv (guanfacine ER): oppositional symptoms
In 217 children with ADHD and oppositional symptoms, guanfacine ER reduced both oppositional and ADHD symptoms more than placebo. Sleepiness was the most common side effect (about half).
RCT, 217 enrolled (138 GXR, 79 placebo): CPRS-R:L oppositional −10.9 vs −6.8 (ES 0.59); ADHD-RS-IV −23.8 vs −11.5 (ES 0.92). Somnolence 50.7%.
Funding / affiliation: Shire-affiliated authors per PubMed record.
Connor DF, Findling RL, Kollins SH, et al. (2010). Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 24(9):755-68. DOI · PubMed 20806988
-
ADHD with tic disorders
In children with ADHD and tics (9 trials), methylphenidate, alpha-2 agonists (clonidine, guanfacine) and atomoxetine improved ADHD symptoms. Alpha-2 agonists and atomoxetine also reduced tics, and methylphenidate did not worsen tics in the short term. Very high doses of dextroamphetamine were linked to worse tics.
Meta-analysis, 9 studies, 477 subjects. ADHD efficacy: MPH, α2 agonists, desipramine, ATX. Tic improvement: α2 agonists and ATX. No evidence MPH worsened tics short-term; supratherapeutic dextroamphetamine worsened tics. Authors: MPH gave the greatest and most immediate ADHD improvement.
Bloch MH, Panza KE, Landeros-Weisenberger A, et al. (2009). Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48(9):884-893. DOI · PubMed 19625978
Off-label uses (not FDA-approved) (1 study)
-
Guanfacine ER in adults (not FDA-approved for adults)
In a Japanese trial in adults, guanfacine ER reduced ADHD symptoms more than placebo (a moderate effect), but about 1 in 5 stopped because of side effects, compared with 3% on placebo. Guanfacine ER is not FDA-approved for adults.
Phase 3 RCT, Japanese adults: ADHD-RS-IV −11.55 vs −7.27 (P=.0005; ES 0.52). TEAEs 81.2% vs 62.0%; discontinuation for TEAEs 19.8% vs 3.0%. Sample size not stated in the abstract (needs full-text check).
Iwanami A, Saito K, Fujiwara M, et al. (2020). Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry 81(3). DOI · PubMed 32297719
Frequently asked questions
Is Intuniv a stimulant?
No. Guanfacine is an alpha-2A adrenergic agonist and is not a controlled substance.
Can Intuniv be taken with a stimulant?
Yes. It is approved both on its own and as add-on therapy to stimulant medicines.
Is it safe to stop Intuniv suddenly?
No. Stopping suddenly can cause a sharp rise in blood pressure. The label recommends lowering the dose by no more than 1 mg every 3–7 days.
Should Intuniv be taken in the morning or evening?
Either. The label allows once-daily dosing in the morning or evening; take it at about the same time each day. Some clinicians suggest evening dosing when daytime sleepiness is a problem (a practice point, not a label instruction).
How long does Intuniv take to work?
It is not a same-day medicine. Doses go up by no more than 1 mg a week, and trials measured benefit over several weeks.
Can Intuniv be crushed or split?
No. Swallow it whole; crushing, chewing or breaking it speeds up the release.
Is generic guanfacine ER the same as regular guanfacine?
No. Extended-release guanfacine (Intuniv and its generics) is not interchangeable milligram for milligram with immediate-release guanfacine tablets.
Which medicines interact with Intuniv?
Drugs that strongly or moderately block CYP3A4 (such as ketoconazole) raise guanfacine levels, and inducers (such as carbamazepine) lower them; doses are adjusted. Other sedating or blood-pressure-lowering drugs can add to its effects.
How is Intuniv different from clonidine ER?
Both are alpha-2 agonists that must be tapered. Intuniv is once daily and more selective for the alpha-2A receptor; clonidine ER tablets are taken twice daily, and Onyda XR is a once-nightly clonidine liquid.
Does Intuniv work all day?
Intuniv is taken once a day, every day, in the morning or evening at about the same time (label section 2.2). The label does not describe hour-by-hour effects; with a half-life of about 18 hours, medicine stays in the blood around the clock once it reaches a steady level (label section 12.3). In trials, benefit was measured over several weeks.
Can Intuniv be taken with food?
Yes, but not with a high-fat meal: the label says high-fat meals raise the amount of medicine in the blood (label section 2.1).
What should I do if I miss a dose of Intuniv?
The Medication Guide says to take the next dose at your regular time and not to take a double dose. If you miss 2 or more doses in a row, talk to your doctor, because you may need to restart at a lower dose (label section 2.6).
What are the most common side effects of Intuniv?
The Medication Guide lists sleepiness, tiredness, trouble sleeping, low blood pressure, nausea, stomach pain, dizziness, dry mouth, irritability, vomiting and slow heart rate (label section 6.1). These are not all the possible side effects; call your prescriber for advice about side effects that bother you.
Can I take Intuniv while pregnant or breastfeeding?
Tell your clinician if you are pregnant or planning a pregnancy. The label says decades of guanfacine use have not shown a higher risk of major birth defects or miscarriage, though use in pregnancy has been infrequent. It is not known whether it passes into human breast milk; if a breastfed baby is exposed, watch for sleepiness, tiredness, or poor feeding. A pregnancy registry for ADHD medicines can be reached at 1-866-961-2388.
Prescribing guidelines
Guidelines generally place stimulants first for most school-age children, adolescents and adults when medication is indicated, with atomoxetine, extended-release guanfacine and extended-release clonidine as evidence-based alternatives or (for the alpha-2 agonists) add-on options. Viloxazine and centanafadine were approved after the 2019 AAP guideline, so it does not address them.
Resources
Sources
- Takeda Pharmaceuticals America, Inc. Intuniv (guanfacine) extended-release tablets. Prescribing Information, revised 06/2025. DailyMed (accessed Oct 2026).
- U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files dated October 2026. FDA.
- U.S. Food and Drug Administration. Drug Shortages database: Guanfacine Hydrochloride Tablet, Extended Release — status Discontinuation (Actavis Pharma, 1–4 mg, posted Nov 13, 2025, business decision), accessed Oct 20, 2026. FDA.
- U.S. Food and Drug Administration. Drug Shortages database, accessed Oct 20, 2026 (no current-shortage entries for atomoxetine, viloxazine, guanfacine, clonidine or centanafadine; guanfacine ER tablets appear only on the discontinuation list). FDA.
- American Society of Health-System Pharmacists. Current Drug Shortage Bulletins list, accessed Oct 20, 2026 (no atomoxetine, viloxazine, guanfacine, clonidine or centanafadine entries). ASHP.
- Wolraich ML, Hagan JF Jr, Allan C, et al.; American Academy of Pediatrics Subcommittee on Children and Adolescents with ADHD. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. AAP.
- Centers for Disease Control and Prevention. Clinical Care of ADHD in Children (summary of the AAP guideline; updated Oct 21, 2026). CDC (accessed 2026).
- Drugs and Lactation Database (LactMed). Guanfacine. National Institute of Child Health and Human Development; revised Nov 2024. NCBI Bookshelf NBK501522.